Cytokine-Induced Neurogenesis in Charcot-Marie-Tooth neuropathy with Connexin 32 Gene Mutation

¹Ochanomizu Health and Longevity Clinic, Tokyo, Japan

²Shirasawa Anti-Aging Medical Institute, Tokyo, Japan

³Livant Neurorecovery Center, Guadalajara, Mexico

*Corresponding author: Takuji Shirasawa, Shirasawa Anti-Aging Medical Institute, Sagawa BLD 701, KandaSurugadai 2-8, Chiyoda-Ku, Tokyo 101-0062, Japan; E-mail: [email protected]

Received Date: May 12, 2023

Publication Date: June 1, 2023

Citation: Shirasawa T, et al. (2023). Cytokine-Induced Neurogenesis in Charcot-Marie-Tooth neuropathy with Connexin 32 Gene Mutation. Mathews J Case Rep. 8(7):118.

Copyright: Shirasawa T, et al. © (2023)

ABSTRACT

Charcot-Marie-Tooth (CMT) neuropathy is one of the most common neuromuscular disorders. Despite the identification of more than 100 causative genes, there are few therapeutic options. We present the case of a 66-year-old man carrying a CMT mutation in the connexin 32 gene with the APOE genotype ε4/ε3 that had exhibited symptoms of slowly progressive muscle weakness and atrophy in the hands and feet and recently developed memory impairment. The muscle weakness, motor dysfunction, and memory impairment symptoms were significantly improved by cytokine-induced neurogenesis combined with physical wave therapy using an arbitrary waveform generator (AWG). Here, we discuss the possible mechanistic basis of how this new treatment ameliorates the symptoms of CMT and propose a novel clinical treatment strategy for CMT.

Keywords: Charcot-Marie-Tooth (CMT) neuropathy, cytokine, wave therapy, neurogenesis, connexin 32